CNBX Pharmaceuticals (8C80) Stock Statistics & Valuation Metrics
Total Valuation
CNBX Pharmaceuticals has a market cap or net worth of EUR 286.60K. The enterprise value is EUR 76.72B.
- Market Cap
- EUR 286.60K
- Enterprise Value
- EUR 76.72B
Share Statistics
CNBX Pharmaceuticals has 1,605,768,100 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 1,605,768,100
- Owned by Insiders
- ―
- Owned by Institutions
- 0.00%
Financial Efficiency
CNBX Pharmaceuticals’s return on equity (ROE) is 0.13 and return on invested capital (ROIC) is 20.91%.
- Return on Equity (ROE)
- 0.13
- Return on Assets (ROA)
- -17.03
- Return on Invested Capital (ROIC)
- 20.91%
- Return on Capital Employed (ROCE)
- 0.11
- Revenue Per Employee
- 0
- Profits Per Employee
- -313.98K
- Employee Count
- 1
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of CNBX Pharmaceuticals is -1.00. CNBX Pharmaceuticals’s PEG ratio is -0.00.
- PE Ratio
- -1.00
- PS Ratio
- 0.00
- PB Ratio
- -0.10
- Price to FCF
- -2.08
- Price to Operating Cash Flow
- -1.71
- PEG Ratio
- -0.00
Income Statement
In the last 12 months, CNBX Pharmaceuticals had revenue of 0 and earned -313.98K in profits. Earnings per share was 0.00.
- Revenue
- 0
- Gross Profit
- 0
- Operating Income
- -271.69K
- Pretax Income
- -313.98K
- Net Income
- -313.98K
- EBITDA
- -273.79K
- Earnings Per Share (EPS)
- 0.00
Cash Flow
In the last 12 months, operating cash flow was -154.17K and capital expenditures -3, giving a free cash flow of -154.17K billion.
- Operating Cash Flow
- -154.17K
- Free Cash Flow
- -154.17K
- Free Cash Flow per Share
- -0.00
Dividends & Yields
CNBX Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -48.00%
- Earnings Yield
- -175.22%
Stock Price Statistics
- Beta
- ―
- 52-Week Price Change
- 0.00%
- 50-Day Moving Average
- 3.88
- 200-Day Moving Average
- 3.88
- Relative Strength Index (RSI)
- ―
- Average Volume (3m)
- 19
Financial Position
CNBX Pharmaceuticals as a current ratio of 0.01, with Debt / Equity ratio of -47.96%
- Current Ratio
- 0.01
- Quick Ratio
- 0.01
- Debt to Market Cap
- 26.42
- Net Debt to EBITDA
- -4.32
- Interest Coverage Ratio
- -6.76
Taxes
In the past 12 months, CNBX Pharmaceuticals has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
CNBX Pharmaceuticals EV to EBITDA ratio is -1.00, with an EV/FCF ratio of -2.80.
- EV to Sales
- 0.00
- EV to EBITDA
- -1.00
- EV to Free Cash Flow
- -2.80
- EV to Operating Cash Flow
- -2.80
Balance Sheet
CNBX Pharmaceuticals has EUR 9,487.00 in cash and marketable securities with EUR 120.00K in debt, giving a net cash position of -EUR 110.51K billion.
- Cash & Marketable Securities
- EUR 9,487.00
- Total Debt
- EUR 120.00K
- Net Cash
- -EUR 110.51K
- Net Cash Per Share
- EUR 0.00
- Tangible Book Value Per Share
- EUR 0.00
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for CNBX Pharmaceuticals is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- 0
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- ―